Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer

Authors

Institutions

Publication Details

Journal
The Breast
Published
2026-01-20
DOI
https://doi.org/10.1016/j.breast.2026.104704
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer

Christina Bjerre, E. H. Jakobsen, Bjørnar Gilje, JA Kyte et al.
The Breast
Advanced Breast Cancer Therapies
article

Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer

Christina Bjerre, E. H. Jakobsen, Bjørnar Gilje, JA Kyte, B. Naume, NK Andresen, R.S. Falk, S. Kaasa, K.G. Svalheim
article en

Abstract

No abstract available for this paper.
The BreastVol. 86
Oslo University Hospital (NO), Stavanger University Hospital (NO), Rigshospitalet (DK), Regionshospital Nordjylland (DK), Dansk Sygehus Institut (DK)
Universitetet i Oslo, Norges Forskningsråd
Good health and well-being
Openalex Percentile: Top 84%
Advanced Breast Cancer Therapies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.